La Jolla Pharmaceutical Company Calls Urgent Special Meeting of

  La Jolla Pharmaceutical Company Calls Urgent Special Meeting of Stockholders
  on February 26, 2010 to Vote on Merger

Business Wire

SAN DIEGO -- February 16, 2010

La Jolla Pharmaceutical Company (NASDAQ: LJPC) today announced that it will
hold a special meeting of stockholders on February 26, 2010 at 3:00 p.m.
Pacific Time to vote on its proposed merger with Adamis Pharmaceuticals
Corporation (OTCBB: ADMP). Anyone who held La Jolla stock as of January 22,
2010 will receive proxy materials and be eligible to vote at the special

It is imperative that La Jolla stockholders vote at this special meeting of
stockholders. Holders of more than 50% of La Jolla’s 65 million shares
outstanding are required to be present in person or represented by proxy to
hold the meeting. For the merger to be completed, holders of more than 50% of
La Jolla’s shares must vote in favor. If too few of La Jolla’s stockholders
vote, or if the merger is not approved, La Jolla will have limited cash
resources, and the La Jolla board of directors may elect to, among other
things, close the business and complete a voluntary dissolution under Delaware

Dr. Deirdre Y. Gillespie, La Jolla’s CEO, stated, “This merger provides
potential upside for La Jolla’s stockholders as Adamis has current and
anticipated future revenues from its recently launched epinephrine syringe and
additional products in the pipeline. To close this deal, La Jolla’s unusually
large base of 12,000 stockholders need to act and vote - every vote is
critical. The likely alternative to the merger is to close the Company, in
which case we currently expect returning $0.02 - $0.03 per share to

There is an extremely limited time to vote as all votes must be received
before Friday, February 26^th. La Jolla’s NASDAQ delisting hearing is
scheduled for February 25^th. Assuming the appeal is unsuccessful, La Jolla
expects that its common stock could be delisted as early as March 1.

This communication shall not constitute an offer to sell or the solicitation
of an offer to sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the requirements of
Section10 of the Securities Act of 1933, as amended.

Additional Information and Where to Find It

The joint proxy statement/prospectus in connection with the merger with Adamis
was mailed to La Jolla stockholders on or about February 12, 2010. Investors
and security holders of both La Jolla and Adamis are urged to read the joint
proxy statement/prospectus because it contains important information about La
Jolla, Adamis and the proposed transaction. The joint proxy
statement/prospectus, and any other documents filed by La Jolla with the SEC,
may be obtained free of charge at the SEC web site at by
contacting La Jolla Investor Relations by e-mail at or by
telephone at 858-452-6600. La Jolla and its respective directors and executive
officers may be deemed to be participants in the solicitation of proxies from
La Jolla’s stockholders in favor of the proposed transaction. Information
about the directors and executive officers of La Jolla and their respective
interests in the proposed transaction is available in the joint proxy

                          FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future results of operations or future financial
performance, including, but not limited to the following statements: the
future operations of Adamis, the expected liquidation value of La Jolla if the
merger is not completed, and the ability to complete the merger with Adamis.
These statements are only predictions and involve known and unknown risks,
uncertainties and other factors, which may cause La Jolla’s actual results to
be materially different from these forward-looking statements. Certain of
these risks, uncertainties, and other factors are described in greater detail
in the joint proxy statement/prospectus, as well as in La Jolla’s filings from
time to time with the SEC, which La Jolla strongly urges you to read and
consider, all of which are available free of charge on the SEC’s web site at La Jolla expressly disclaims any intent to update any
forward-looking statements.


La Jolla Pharmaceutical Company
Gail A. Sloan
Vice President of Finance and Secretary
Press spacebar to pause and continue. Press esc to stop.